6月9日，化学制品、医疗服务、生物制品、中药、医药商业多个板块联动效应明显。概念板块中，减肥 药、创新药、阿兹海默、肝素概念集体飘红，引发市场对医药行业基本面的广泛关注。 中国金融智库特邀研究员余丰慧向《证券日报》记者表示，这主要受到几方面因素的驱动。首先，全球 对医疗健康产品和服务的需求持续增长；其次，各国政府加大对医药行业的政策支持和资金投入，推动 了创新药物的研发和市场准入；再者，人口老龄化的加剧以及慢性病发病率的上升，增加了对医药产品 的长期需求。此外，技术进步如生物技术的发展也为医药行业带来了新的增长点。 据披露，此次三生制药与辉瑞就该款药物的授权协议总额高达60.5亿美元，已经打破了此前国产创新药 产品出海创下的纪录。 此外，采访中，记者了解到，2025年医药行业正迎来"价值重塑期"。国内药企通过license-out(对外许可) 模式深度融入全球产业链，技术授权交易日益频繁。以江苏恒瑞医药（600276）股份有限公司、信达生 物制药(苏州)有限公司为代表的头部企业，凭借创新管线在海外临床及商业化合作中取得关键突破，推 动板块估值中枢持续上移。 细分领域中，创新药无疑是最近二级市场的关注焦点。日前 ...

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 中国创新药在 ASCO 表现超预期，关注信达 生物、科伦博泰等 增持（维持） [Table_Tag] [Table_Summary] 投资要点 ◼ 环码生物 RNA 创新药获 FDA IND 默示许可；PROTAC 雌激素受体降 解剂向 FDA 递交 NDA；国产九价 HPV 疫苗获批上市，填补高端疫苗 空白 6 月 6 日，环码生物宣布，其自研的环形 RNA 新药 HM2002 获 FDA 新药临床试验申请（IND）默示许可。该药为全球首款完成患者给 药的环形 RNA 类药物，曾于 1 月获中国 NMPA IND 批准。6 月 7 日， Arvinas 与辉瑞联合宣布，已向 FDA 递交 Vepdegestrant 的新药申请 （NDA），该药为全球首个口服 PROTAC 雌激素受体降解剂，适用于 ER+/HER2-乳腺癌患者。6 月 4 日，由翔安实验室与厦门大学等联合研 制的国产九价 HPV 疫苗获国家药监局批准上市，成为我国首个自主供 应的九价 HPV 疫苗，标志中国正式成为继美国后第二个具备高价 HPV 疫苗自主可控能力的国家。 ◼ 具体配 ...

Group 1 - The Hong Kong innovative drug sector is undergoing an unprecedented wave of value reassessment, with around 12 innovative drug concept stocks rising over 50% year-to-date, including Rongchang Biopharma and Sanofi Biotech, which have surged over 200% [1] - The ASCO annual meeting served as a key catalyst, showcasing over 70 research results from Chinese pharmaceutical companies, with Innovent Biologics' IBI363 clinical data generating significant attention due to its breakthrough efficacy in treating advanced non-small cell lung cancer [2] - License-out transactions have become a core engine for valuation reshaping, with 41 outbound transactions totaling $36.93 billion in Q1 2025, nearing the total for the entire year of 2023 [3] Group 2 - Domestic drug approvals are accelerating, with the National Medical Products Administration approving 11 innovative drugs from 8 companies, including 9 domestically developed drugs, indicating a robust pipeline for commercialization [4] - The policy environment is favorable, with the National Healthcare Security Administration constructing a multi-tiered payment system to support innovative drugs throughout their lifecycle, enhancing the attractiveness of the sector [5] - The pharmaceutical sector is expected to see strong performance in H1 2025, driven by favorable external conditions and the ongoing trend of self-sufficiency in drug development [6]

Group 1 - The US claims that China has violated the consensus reached during the Geneva trade talks, while China's Ministry of Commerce firmly rejects these accusations and urges the US to correct its erroneous actions [2] - The A-share market is expected to experience downward pressure in the short term due to various disturbances, but institutions remain optimistic about structural opportunities, particularly in dividend assets, growth, and consumption sectors [2][3] - The EU expresses regret over the US's decision to increase tariffs on steel and aluminum, which adds to economic uncertainty across the Atlantic [2] Group 2 - China's manufacturing PMI rose by 0.5 percentage points in May, indicating improved manufacturing sentiment, while the export container freight index has also rebounded [3] - The People's Bank of China conducted a 700 billion yuan reverse repurchase operation in May to maintain liquidity in the banking system, despite a net withdrawal of 200 billion yuan [3] - The Ministry of Ecology and Environment plans to establish around 100 key laboratories by 2035 to enhance environmental science and technology in China [3] Group 3 - In the first four months of the year, China's total social logistics amounted to 115.3 trillion yuan, a year-on-year increase of 5.6% [4] - During the Dragon Boat Festival holiday, an estimated 657 million people are expected to travel across regions in China, reflecting a 3.0% year-on-year increase [4] Group 4 - The Hang Seng Index closed down 0.57% at 23,157.97 points, with significant declines in pharmaceutical and real estate stocks [5] - As of June 3, 28 listed companies have successfully removed their ST (special treatment) status this year, primarily through financial improvements and restructuring [5][6] Group 5 - 104 private equity firms have emerged as major holders in 97 newly listed ETFs, with a total of 1.783 billion shares held, indicating strong interest in ETFs [6] - *ST Hengli is under investigation by the China Securities Regulatory Commission for suspected false disclosures in its financial reports [6] Group 6 - The automotive industry is facing declining profitability due to intense competition, with profit margins expected to drop to 4.3% in 2024 [9] - In the first five months, the top 100 real estate companies in China acquired land worth 405.19 billion yuan, a year-on-year increase of 28.8% [9] Group 7 - The South Korean government is holding an emergency meeting with major steel manufacturers to discuss the impact of increased US tariffs on steel and aluminum [9] - India's government has finalized a new electric vehicle policy allowing companies to import EVs at a reduced tariff, contingent on local manufacturing investments [10] Group 8 - The global airline industry is projected to achieve a net profit of $36 billion in 2025, showing improvement from previous forecasts [10] - Chinese biopharmaceutical company has reported promising results from a clinical trial for a lung cancer treatment, outperforming a leading competitor [11] Group 9 - Tesla's sales in Europe have significantly declined, with France experiencing a 67% drop in sales [11] - Meta Platforms aims to enable brands to fully utilize AI for ad creation by the end of next year [11] Group 10 - The US Treasury is facing scrutiny over its debt levels, with concerns that rising debt could trigger a global bond market crisis [12] - The ISM manufacturing PMI for the US in May was reported at 48.5, indicating contraction in the manufacturing sector [12] Group 11 - The UK government plans to expand its nuclear submarine fleet amid rising geopolitical tensions [13] - Japan is expected to engage in new trade negotiations with the US, with a potential agreement anticipated soon [13] Group 12 - The US steel stocks surged following the announcement of increased tariffs, with companies like Steel Dynamics seeing gains of over 10% [15] - The three major US stock indices experienced slight gains, with notable performances from companies like Nike and Boeing [15] Group 13 - European stock indices showed mixed results, with Germany's DAX index declining by 0.28% [16] - Major Asian stock indices also had varied performances, with Japan's Nikkei 225 dropping by 1.3% [16] Group 14 - Concerns over the US's growing federal budget deficit have led investment firms to shift away from long-term US Treasury bonds [17] - US Treasury yields have collectively risen, with the 30-year yield reaching 4.963% [17] Group 15 - International precious metals futures saw widespread gains, with COMEX gold futures rising by 2.74% [18] - Oil prices increased significantly, with US crude oil futures rising by 3.7% [18] Group 16 - Goldman Sachs is investigating potential tariffs on copper imports following the US's increase in steel and aluminum tariffs [19] - The firm has adjusted its aluminum price forecasts for 2025, reflecting market dynamics [19] Group 17 - The US dollar index fell by 0.75%, with most non-US currencies appreciating against the dollar [20] - Morgan Stanley predicts that the dollar will decline significantly by mid-next year due to economic factors [20]